首页> 外文期刊>Clinical pharmacokinetics >Recombinant human erythropoietin for the treatment of renal anaemia in children: no justification for bodyweight-adjusted dosage.
【24h】

Recombinant human erythropoietin for the treatment of renal anaemia in children: no justification for bodyweight-adjusted dosage.

机译:重组人促红细胞生成素用于治疗儿童肾性贫血:没有理由调整体重。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Drug doses for children are usually calculated by reducing adult doses in proportion to bodyweight. The clinically effective dose of recombinant human erythropoietin (epoetin) in children, however, seems to be higher than predicted by this calculation. OBJECTIVE: To determine the quantitative relationship between epoetin dose, bodyweight and response in children with end-stage renal disease. PATIENTS AND METHODS: The time-course of haemoglobin in 52 children during long-term treatment with epoetin beta was analysed by population pharmacodynamic modelling. Patients were 5-20 years old and weighed 16-53kg at the beginning of treatment. Epoetin beta was given intravenously three times per week after haemodialysis. Doses ranged from 110 to 7500IU (3-205 IU/kg). Haemoglobin versus time was described by assuming that the haemoglobin level rises after each dose due to the formation of new red blood cells, which then survive according to a logistic function. The initial rise after each dose was modelled in terms of absolute dose (not dose/kg). A parametric analysis was done with NONMEM, followed by a nonparametric analysis with NPAG. RESULTS: Dose-response was best described by a sigmoid maximum-effect (E(max)) model with median E(max) = 0.29 g/dL, median 50% effective dose (ED(50)) = 2400IU and shape parameter gamma = 2. The estimated median survival time of the epoetin-induced red blood cells, tau, was 76 days. Neither of the dose-response parameters E(max) and ED(50) showed dependence on bodyweight. The median haemoglobin response to a standard dose, 0.042 g/dL for 1000IU, was similar to that reported for adults with intravenous administration. CONCLUSIONS: Doses for children in this age range should be specified as absolute amounts rather than amounts per unit bodyweight. Initial doses can be calculated individually, based on haemoglobin level before treatment, the desired haemoglobin at steady state and the median population parameters E(max), ED(50) and tau.
机译:背景:用于儿童的药物剂量通常是通过按体重减少成人剂量来计算的。然而,重组人促红细胞生成素(epoetin)在儿童中的临床有效剂量似乎高于该计算所预测的剂量。目的:确定终末期肾脏疾病患儿中依泊汀剂量,体重与反应之间的定量关系。病人和方法:通过群体药效学模型分析了52名儿童长期使用依泊汀β治疗期间血红蛋白的时程。患者年龄为5-20岁,在治疗开始时体重为16-53kg。血液透析后,每周三次静脉注射伊波汀β。剂量范围为110至7500IU(3-205 IU / kg)。血红蛋白与时间的关系是通过假设每次给药后血红蛋白水平由于形成新的红细胞而增加而描述的,然后根据逻辑功能存活。每个剂量后的初始上升均以绝对剂量(而非剂量/ kg)为模型。使用NONMEM进行参数分析,然后使用NPAG进行非参数分析。结果:剂量反应最好用S型最大效应(E(max))模型描述,中位数E(max)= 0.29 g / dL,中位数50%有效剂量(ED(50))= 2400IU,形状参数γ =2。依泊汀诱导的红细胞的估计中位生存时间tau为76天。剂量反应参数E(max)和ED(50)均未显示出对体重的依赖性。对1000IU的标准剂量0.042 g / dL的血红蛋白中值反应与成人静脉给药的报道相似。结论:该年龄段儿童的剂量应指定为绝对剂量,而不是单位体重的剂量。初始剂量可以根据治疗前的血红蛋白水平,稳定状态下所需的血红蛋白以及中位总体参数E(max),ED(50)和tau进行单独计算。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号